Staidson Beijing Biopharma

Price Chart

Risk-Adjusted Performance

Staidson Beijing Biopharma (300204) Price Performance

Staidson Beijing Biopharma (300204) trades on SHE in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY29.87, down 1.52% from the previous close.

Over the past year, 300204 has traded between a low of CNY10.31 and a high of CNY61.00. The stock has gained 176.3% over this period. It is currently 51.0% below its 52-week high.

Staidson Beijing Biopharma has a market capitalization of $14.49B.

About Staidson Beijing Biopharma

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Troponium Chloride Capsules, Gliclazide extended-release tablets, Aspirin enteric-coated tablets, Compound polyethylene glycol (3350) electrolyte oral solution, Compound polyethylene glycol (3350) electrolyte vitamin C. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.

Compare Staidson Beijing Biopharma

Side-by-side comparison against top Healthcare peers.